Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.
Combination approaches using systemic immunotherapy agents are now standard of care for patients with advanced-stage hepatocellular carcinoma (HCC), resulting in improved overall survival. However, even with optimal systemic regimens, fewer than 40% of cases respond to treatment, presumably due to resistance mechanisms...